TCTR20210316012已完成4 期
Effects of low dose oral tolvaptan add on benefit in patients hospitalized for acute decompensated heart failure: A randomized controlled trial
/A0 个研究点目标入组 40 人开始时间: 2021年3月16日最近更新:
适应症
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 发起方
- 入组人数
- 40
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 Years 至 N/A (No limit)（—）
- 性别
- All
入选标准
- •1 Age more than 18 years
- •2 Acute decompensated HF
- •3 Admission within 48 hr
- •4 Plasma Na less than 145 mEq/L
- •5 Informed consent
排除标准
- •1 Hemodynamic unstable
- •2 AKI or advanced ESRD
- •3 Severe hepatitis
- •4 Pregnancy or breastfeeding
- •5 Major surgery within 60 days
- •6 Hypersensitivity to the active substance
研究者
相似试验
已完成
不适用
Study of the safety and efficacy of tolvaptan for fluid retention symptoms of right heart failure due to pulmonary hypertensiopulmonary hypertensionJPRN-UMIN000010196Department of Cardiology, Keio University School of Medicine40
已完成
不适用
ong-term Effect of Tolvaptan Administration for Outcome and Neurohormonal Factors in Patients with Heart Failureheart failureJPRN-UMIN000013807ihon University Surugadai Hospital100
尚未招募
4 期
A study on the safety and efficasy of tolvaptan for patients with fluid retention after cardiothoracic surgeryPatients received cardiothoracic surgery with congestive heart failure.JPRN-UMIN000011172Osaka city university graduate school of medicine210
已完成
不适用
ongitudinal Efficacy and Safety Study of Tolvaptan on Autosomal Dominant Polycystic Kidney Disease PatientsAutosomal Dominant Polycystic Kidney DiseaseJPRN-UMIN000021267Autosomal Dominant Polycystic Kidney Disease Research Section, Kyorin University, School of Medicine119
招募中
不适用
A study to evaluate effect and safety of Tolvaptan in Nephrogenic Diabetes Insipidus caused by mutations in the vasopressin type 2 receptor gene.ephrogenic Diabetes Insipidus caused by mutations in the vasopressin type 2 receptor geneJPRN-UMIN000021708Department of Nephrology and Endocrinology, The University of Tokyo Hospital3